Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk
- PMID: 17719770
- PMCID: PMC2715949
- DOI: 10.1016/j.jsbmb.2007.05.012
Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk
Abstract
Multiple lines of evidence support a central role of hormones in the etiology of breast cancer. In epidemiologic studies, considerable effort has focused on delineating the role of endogenous hormones in risk of breast cancer among postmenopausal women. Recently, substantial additional data has accrued from prospective studies where endogenous hormones are measured in study subjects prior to disease diagnosis. In this review, the epidemiologic evidence linking sex steroids--estrogens, testosterone, and progesterone, specifically--with subsequent risk of breast cancer in both premenopausal and postmenopausal women is summarized. Overall, a strong positive association between breast cancer risk and circulating levels of both estrogens and testosterone has now been well confirmed among postmenopausal women; women with hormone levels in the top 20% of the distribution (versus bottom 20%) have a two- to three-fold higher risk of breast cancer. Evidence among premenopausal women is more limited, though increased risk associated with higher levels of testosterone is consistent. However, both positive and null associations have been observed with estrogens and progesterone and clearly more evaluation is needed.
Similar articles
-
Endogenous hormones and risk of breast cancer in postmenopausal women.Breast Dis. 2005-2006;24:3-15. doi: 10.3233/bd-2006-24102. Breast Dis. 2005. PMID: 16917136 Review.
-
Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies.Adv Exp Med Biol. 2008;630:148-65. Adv Exp Med Biol. 2008. PMID: 18637490 Review.
-
Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers.Steroids. 2015 Jul;99(Pt A):8-10. doi: 10.1016/j.steroids.2014.12.013. Epub 2014 Dec 30. Steroids. 2015. PMID: 25555473 Review.
-
Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II.Breast Cancer Res. 2013 Mar 6;15(2):R19. doi: 10.1186/bcr3394. Breast Cancer Res. 2013. PMID: 23497468 Free PMC article.
-
Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.J Natl Cancer Inst. 2006 Oct 4;98(19):1406-15. doi: 10.1093/jnci/djj376. J Natl Cancer Inst. 2006. PMID: 17018787
Cited by
-
Lignans and breast cancer risk in pre- and post-menopausal women: meta-analyses of observational studies.Br J Cancer. 2009 May 5;100(9):1492-8. doi: 10.1038/sj.bjc.6605003. Epub 2009 Mar 31. Br J Cancer. 2009. PMID: 19337250 Free PMC article.
-
Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer.Breast Cancer Res. 2015 Sep 4;17(1):123. doi: 10.1186/s13058-015-0636-6. Breast Cancer Res. 2015. PMID: 26341737 Free PMC article.
-
Associations of established breast cancer risk factors with urinary estrogens in postmenopausal women.Cancer Causes Control. 2022 Feb;33(2):279-291. doi: 10.1007/s10552-021-01528-9. Epub 2022 Jan 6. Cancer Causes Control. 2022. PMID: 34988766 Free PMC article.
-
Does iron have a role in breast cancer?Lancet Oncol. 2008 Aug;9(8):803-7. doi: 10.1016/S1470-2045(08)70200-6. Lancet Oncol. 2008. PMID: 18672216 Free PMC article. Review.
-
Pathogenetic mechanisms of heavy metals effect on proapoptotic and proliferative potential of breast cancer.Interv Med Appl Sci. 2015 Jun;7(2):63-8. doi: 10.1556/1646.7.2015.2.4. Epub 2015 Jun 11. Interv Med Appl Sci. 2015. PMID: 26120478 Free PMC article.
References
-
- van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, Fraser G, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152:514–527. - PubMed
-
- Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296–300. - PubMed
-
- Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–2139. - PubMed
-
- Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. 2000;21:427–433. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical